Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma
- 1 May 2001
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 8 (5) , 378-387
- https://doi.org/10.1038/sj.cgt.7700315
Abstract
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.Keywords
This publication has 46 references indexed in Scilit:
- Autologous Antileukemic Immune Response Induced by Chronic Lymphocytic Leukemia B Cells Expressing the CD40 Ligand and Interleukin 2 TransgenesHuman Gene Therapy, 2001
- Adenovirus vectors for gene deliveryCurrent Opinion in Biotechnology, 1999
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- CD40‐CD40 ligand interactions stimulate B cell antigen processingEuropean Journal of Immunology, 1995
- Low doses of rIL2 after autologous bone marrow transplantation induce a “prolonged” immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomasAnnals of Hematology, 1995
- Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphomaCancer, 1995
- Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti‐mouse CD40 antibodiesEuropean Journal of Immunology, 1994
- In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.The Journal of Experimental Medicine, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their TumorsNew England Journal of Medicine, 1992